ITMI20131944A1 - Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale - Google Patents

Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale

Info

Publication number
ITMI20131944A1
ITMI20131944A1 IT001944A ITMI20131944A ITMI20131944A1 IT MI20131944 A1 ITMI20131944 A1 IT MI20131944A1 IT 001944 A IT001944 A IT 001944A IT MI20131944 A ITMI20131944 A IT MI20131944A IT MI20131944 A1 ITMI20131944 A1 IT MI20131944A1
Authority
IT
Italy
Prior art keywords
viral vector
gene transfer
eucariotic
cell
eucariotic cell
Prior art date
Application number
IT001944A
Other languages
English (en)
Inventor
Silke Krol
Maria Pelliccia
Francesco Stellacci
Original Assignee
Fond I R C C S Istituto Neur Ologico Carlo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond I R C C S Istituto Neur Ologico Carlo filed Critical Fond I R C C S Istituto Neur Ologico Carlo
Priority to IT001944A priority Critical patent/ITMI20131944A1/it
Priority to EP14194020.5A priority patent/EP2875831A1/en
Publication of ITMI20131944A1 publication Critical patent/ITMI20131944A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IT001944A 2013-11-21 2013-11-21 Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale ITMI20131944A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT001944A ITMI20131944A1 (it) 2013-11-21 2013-11-21 Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale
EP14194020.5A EP2875831A1 (en) 2013-11-21 2014-11-20 A method of genic transfer into an eukaryotic cell through a viral vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001944A ITMI20131944A1 (it) 2013-11-21 2013-11-21 Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale

Publications (1)

Publication Number Publication Date
ITMI20131944A1 true ITMI20131944A1 (it) 2015-05-22

Family

ID=49780201

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001944A ITMI20131944A1 (it) 2013-11-21 2013-11-21 Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale

Country Status (2)

Country Link
EP (1) EP2875831A1 (it)
IT (1) ITMI20131944A1 (it)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100787A2 (en) * 2006-02-28 2007-09-07 Massachusetts Institute Of Technology Nanoparticles having sub-nanometer features

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100787A2 (en) * 2006-02-28 2007-09-07 Massachusetts Institute Of Technology Nanoparticles having sub-nanometer features

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MO STEVEN ET AL: "Coating of adenovirus type 5 with cleavable PEGylated gold nanoparticles for enhanced protection and circulation", HUMAN GENE THERAPY, vol. 24, no. 5, S 8.4, May 2013 (2013-05-01), & CONFERENCE OF THE BRITISH-SOCIETY-FOR-GENE-AND-CELL-THERAPY (BSGCT); EGHAM, UK; APRIL 17 -19, 2013, pages A13, XP002719082 *
PELLICCIA M.: "Gold nanoparticles functionalized with sulfonate ligands as anit-viral agents", no. Abstr.64, 23 July 2012 (2012-07-23) - 24 July 2012 (2012-07-24), Seattle, WA, USA, XP002719084, Retrieved from the Internet <URL:http://depts.washington.edu/nanobio/wordpress/wp-content/uploads/2012/06/NanoBio2012_Poster_Abstracts.pdf> [retrieved on 20140121] *
VERMA A. & STELLACCI F.: "Effect of surace properties on nanoparticle-cell interactions", SMALL, vol. 6, no. 1, 2010, pages 12 - 21, XP002719085 *
WANG Y. ET AL.: "A novel method for viral gne delivery in solid tumors", CANCER RES., vol. 65, 2005, pages 7541 - 7545, XP002719083 *

Also Published As

Publication number Publication date
EP2875831A1 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
DK3332019T3 (da) Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
DK3351620T3 (da) Metabolsk optimeret cellekultur
EP3063721A4 (en) SYSTEM AND METHOD FOR PERFORMANCE-BASED ROUTING OF INTERACTIONS IN A CALL CENTER
IL244791A0 (en) Methods for modifying a host cell
DK3071223T3 (da) Cell
EP2968549A4 (en) CELL CULTURE METHODS
DK3047013T3 (da) Fremgangsmåder og systemer til forarbejdning af en cellekultur
EP2971014A4 (en) CELL CULTURE METHODS
HK1224335A1 (zh) 使用合成信使 無飼養層衍生人誘導多能幹細胞
DK3014641T3 (da) Biokemisk energiomdannelsescelle
IL239824A0 (en) Use of inos inhibitors to increase viral survival in culture
DK3000526T3 (da) Fremgangsmåde til overførsel af præcise små volumen væsker
IL245392A0 (en) A method for cell culture
DK3567099T3 (da) Nyrecellepopulationer og anvendelser deraf
HK1219500A1 (zh) 遺傳穩定的溶瘤性 病毒、其製備方法及用途
DK3412684T3 (da) Nye selektionsvektorer og fremgangsmåder til selektering af eukaryotiske værtsceller
DK3365107T3 (da) Cellekultur
EP3050961A4 (en) Method for improving efficiency of inducing pluripotent stem cell
EP2970960A4 (en) nucleic acid amplification
HRP20200145T1 (hr) Spojevi i metode za poboljšavanje transfera virusnog gena u humane hematopoetske stanice
DK3077523T3 (da) Produktion af thapsigarginer ved hjælp af Thapsia cellesuspensionskultur
DK2978839T3 (da) Fremgangsmåde til celledyrkning
FI20136286A (fi) Menetelmä käytettyjen kestokatodilevyjen huoltamiseksi
ITMI20131944A1 (it) Metodo di trasferimento genico in una cellula eucariotica mediante un vettore virale
EP3008174A4 (en) Method of efficiently establishing induced pluripotent stem cells